Base de dados : MEDLINE
Pesquisa : D03.132.327.287.730 [Categoria DeCS]
Referências encontradas : 341 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 35 ir para página                         

  1 / 341 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28085074
[Au] Autor:Laudy AE; Kulinska E; Tyski S
[Ad] Endereço:Department of Pharmaceutical Microbiology, Medical University of Warsaw, Oczki 3 Str., 02-007 Warsaw, Poland. alaudy@wp.pl.
[Ti] Título:The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.
[So] Source:Molecules;22(1), 2017 Jan 11.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The potential role of non-antibiotic medicinal products in the treatment of multidrug-resistant Gram-negative bacteria has recently been investigated. It is highly likely that the presence of efflux pumps may be one of the reasons for the weak activity of non-antibiotics, as in the case of some non-steroidal anti-inflammatory drugs (NSAIDs), against Gram-negative rods. The activity of eight drugs of potential non-antibiotic activity, active substance standards, and relevant medicinal products were analysed with and without of efflux pump inhibitors against 180 strains of five Gram-negative rod species by minimum inhibitory concentration (MIC) value determination in the presence of 1 mM MgSO4. Furthermore, the influence of non-antibiotics on the susceptibility of clinical strains to quinolones with or without PAßN (Phe-Arg-ß-naphthylamide) was investigated. The impacts of PAßN on the susceptibility of bacteria to non-antibiotics suggests that amitriptyline, alendronate, nicergoline, and ticlopidine are substrates of efflux pumps in Gram-negative rods. Amitriptyline/Amitriptylinum showed the highest direct antibacterial activity, with MICs ranging 100-800 mg/L against all studied species. Significant decreases in the MIC values of other active substances (acyclovir, atorvastatin, and famotidine) tested with pump inhibitors were not observed. The investigated non-antibiotic medicinal products did not alter the MICs of quinolones in the absence and in the presence of PAßN to the studied clinical strains of five groups of species.
[Mh] Termos MeSH primário: Amitriptilina/farmacologia
Antibacterianos/farmacologia
Dipeptídeos/farmacologia
Genes MDR/efeitos dos fármacos
Pseudomonas aeruginosa/efeitos dos fármacos
[Mh] Termos MeSH secundário: Aciclovir/farmacologia
Alendronato/farmacologia
Atorvastatina Cálcica/farmacologia
Combinação de Medicamentos
Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos
Farmacorresistência Bacteriana Múltipla/genética
Escherichia coli/efeitos dos fármacos
Escherichia coli/crescimento & desenvolvimento
Escherichia coli/metabolismo
Famotidina/farmacologia
Klebsiella pneumoniae/efeitos dos fármacos
Klebsiella pneumoniae/crescimento & desenvolvimento
Klebsiella pneumoniae/metabolismo
Sulfato de Magnésio/farmacologia
Testes de Sensibilidade Microbiana
Nicergolina/farmacologia
Pseudomonas aeruginosa/crescimento & desenvolvimento
Pseudomonas aeruginosa/metabolismo
Quinolonas/farmacologia
Salmonella/efeitos dos fármacos
Salmonella/crescimento & desenvolvimento
Salmonella/metabolismo
Ticlopidina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Dipeptides); 0 (Drug Combinations); 0 (Quinolones); 0 (phenylalanylarginine-naphthylamide); 1806D8D52K (Amitriptyline); 48A5M73Z4Q (Atorvastatin Calcium); 5QZO15J2Z8 (Famotidine); 7487-88-9 (Magnesium Sulfate); JCV8365FWN (Nicergoline); OM90ZUW7M1 (Ticlopidine); X1J18R4W8P (Alendronate); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE


  2 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27209695
[Au] Autor:Pluhácek T; Hanzal J; Hendrych J; Milde D
[Ti] Título:Microwave-assisted digestion using nitric acid for heavy metals and sulfated ash testing in active pharmaceutical ingredients.
[So] Source:Pharmazie;71(4):177-80, 2016 Apr.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The monitoring of inorganic impurities in active pharmaceutical ingredients plays a crucial role in the quality control of the pharmaceutical production. The heavy metals and residue on ignition/sulfated ash methods employing microwave-assisted digestion with concentrated nitric acid have been demonstrated as alternatives to inappropriate compendial methods recommended in United States Pharmacopoeia (USP) and European Pharmacopoeia (Ph. Eur.). The recoveries using the heavy metals method ranged between 89% and 122% for nearly all USP and Ph. Eur. restricted elements as well as the recoveries of sodium sulfate spikes were around 100% in all tested matrices. The proposed microwave-assisted digestion method allowed simultaneous decomposition of 15 different active pharmaceutical ingredients with sample weigh up to 1 g. The heavy metals and sulfated ash procedures were successfully applied to the determination of heavy metals and residue on ignition/sulfated ash content in mycophenolate mofetil, nicergoline and silymarin.
[Mh] Termos MeSH primário: Contaminação de Medicamentos
Metais Pesados/análise
Ácido Nítrico/química
Sulfatos/análise
[Mh] Termos MeSH secundário: Indicadores e Reagentes
Micro-Ondas
Ácido Micofenólico/análogos & derivados
Ácido Micofenólico/análise
Nicergolina/análise
Controle de Qualidade
Silimarina/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Indicators and Reagents); 0 (Metals, Heavy); 0 (Silymarin); 0 (Sulfates); 411VRN1TV4 (Nitric Acid); HU9DX48N0T (Mycophenolic Acid); JCV8365FWN (Nicergoline)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:161126
[Lr] Data última revisão:
161126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160524
[St] Status:MEDLINE


  3 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26450366
[Au] Autor:Walford T; Musa FI; Harper AG
[Ad] Endereço:Institute for Science and Technology in Medicine, Keele University, Guy Hilton Research Centre, Stoke-on-Trent, Staffordshire, UK.
[Ti] Título:Nicergoline inhibits human platelet Ca(2+) signalling through triggering a microtubule-dependent reorganization of the platelet ultrastructure.
[So] Source:Br J Pharmacol;173(1):234-47, 2016 Jan.
[Is] ISSN:1476-5381
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: Recently, we demonstrated that a pericellular Ca(2+) recycling system potentiates agonist-evoked Ca(2+) signalling and granule secretion in human platelets and hypothesized a role for the membrane complex (MC) in orchestrating the accumulation of Ca(2+) in the pericellular region. Previous work has demonstrated that treatment with high concentrations of nicergoline may disrupt the MC through an ability to trigger a re-organization of the dense tubular system. Experiments were therefore performed to assess whether nicergoline-induced changes in platelet ultrastructure affects thrombin-evoked Ca(2+) fluxes and dense granule secretion. EXPERIMENTAL APPROACH: Thrombin-evoked Ca(2+) fluxes were monitored in Fura-2- or Fluo-5N-loaded human platelets, or using platelet suspensions containing Fluo-4 or Rhod-5N K(+) salts. Fluorescence microscopy was utilized to monitor microtubule structure and intracellular Ca(2+) store distribution in TubulinTracker- and Fluo-5N-loaded platelets respectively. Dense granule secretion was monitored using luciferin-luciferase. KEY RESULTS: Nicergoline treatment inhibited thrombin-evoked Ca(2+) signalling and induced alterations in the microtubule structure and the distribution of intracellular Ca(2+) stores in platelets. Nicergoline altered the generation and spreading of thrombin-induced pericellular Ca(2+) signals and almost completely prevented dense granule secretion. Stabilization of microtubules using taxol reversed most effects of nicergoline on platelet Ca(2+) signalling and partially reversed its effects on dense granule secretion. CONCLUSIONS AND IMPLICATIONS: Nicergoline-induced alterations to platelet ultrastructure disrupt platelet Ca(2+) signalling in a manner that would be predicted if the MC had been disrupted. These data suggest that nicergoline may be a useful prototype for the discovery of novel MC-disrupting anti-thrombotics.
[Mh] Termos MeSH primário: Plaquetas/efeitos dos fármacos
Plaquetas/ultraestrutura
Sinalização do Cálcio/efeitos dos fármacos
Microtúbulos/efeitos dos fármacos
Nicergolina/farmacologia
[Mh] Termos MeSH secundário: Plaquetas/metabolismo
Cálcio/metabolismo
Seres Humanos
Microscopia de Fluorescência
Microtúbulos/ultraestrutura
Nicergolina/antagonistas & inibidores
Paclitaxel/farmacologia
Vesículas Secretórias/efeitos dos fármacos
Trombina/antagonistas & inibidores
Trombina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
EC 3.4.21.5 (Thrombin); JCV8365FWN (Nicergoline); P88XT4IS4D (Paclitaxel); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151010
[St] Status:MEDLINE
[do] DOI:10.1111/bph.13361


  4 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26669004
[Au] Autor:Zeng XF; Liu J; Song M; Hang TJ
[Ti] Título:[Identification of related substances in nicergoline by HPLC-MS].
[So] Source:Yao Xue Xue Bao;50(8):1026-31, 2015 Aug.
[Is] ISSN:0513-4870
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To study the related substances in nicergoline, electrospray positive ionization high resolution TOF/MS was used for the determination of the accurate mass and elemental composition of the related substances. Triple quadrupoles tandem MS/MS was employed for the determination of the fragmentations of the parent ions. 16 related substances were detected and identified to be eight synthetic by-products and eight degradation products, by using impurity references matching, product mass spectra fragmentations elucidation, and verified further according to synthetic processes and stress testing results. The results obtained are valuable for nicergoline manufacturing process control and quality assurance.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão
Nicergolina/química
Espectrometria de Massas em Tandem
[Mh] Termos MeSH secundário: Nicergolina/síntese química
Controle de Qualidade
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
JCV8365FWN (Nicergoline)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:151216
[Lr] Data última revisão:
151216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151217
[St] Status:MEDLINE


  5 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25712664
[Au] Autor:Zajdel P; Bednarski M; Sapa J; Nowak G
[Ad] Endereço:Department of Medicinal Chemistry, Jagiellonian University Medical College, Kraków, Poland. Electronic address: pawel.zajdel@uj.edu.pl.
[Ti] Título:Ergotamine and nicergoline - facts and myths.
[So] Source:Pharmacol Rep;67(2):360-3, 2015 Apr.
[Is] ISSN:1734-1140
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Ergotamine, being a representative of naturally occurring ergoline alkaloids, derived from d-lysergic acid, and nicergoline, a d-lumilysergic acid derivative belonging to semi-synthetic ergot-derived alkaloids, display diversified affinity for adrenergic, serotoninergic, and dopamine receptors. Although introduction of triptans marginalized use of ergotamine, nicergoline is used in cerebral metabolic-vascular disorders, and dementia. Additionally, nicergoline exhibits a safety profile comparable to that of placebo, and none of the reviewed studies reported any incidence of fibrosis or ergotism with nicergoline treatment. In line with the recent data, activation of 5-HT2B receptor by ergot derivatives i.e. ergotamine, methysergide, pergolide, and carbegoline is involved in pathogenesis of drug-induced valvulopathy. In contrary structurally related drugs - lisuride and terguride do not increase the risk of valvular heart disease. It seems, that more detailed mechanistic studies on nicergoline and ergotamine might be beneficial for determining structural requirements related to activation of G-protein as well as alternative signal transduction pathways e.g. ß-arrestins or different kinases, and responsible for drug liabilities.
[Mh] Termos MeSH primário: Ergotamina/efeitos adversos
Doenças das Valvas Cardíacas/induzido quimicamente
Nicergolina/efeitos adversos
[Mh] Termos MeSH secundário: Ergotamina/farmacologia
Ergotamina/uso terapêutico
Seres Humanos
Nicergolina/farmacologia
Nicergolina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
JCV8365FWN (Nicergoline); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:150225
[Lr] Data última revisão:
150225
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150226
[St] Status:MEDLINE


  6 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25625360
[Au] Autor:Lee YC; Kim SY
[Ad] Endereço:Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea.
[Ti] Título:Treatment of neurotrophic keratopathy with nicergoline.
[So] Source:Cornea;34(3):303-7, 2015 Mar.
[Is] ISSN:1536-4798
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The aim of this study was to determine the effect of nicergoline in patients with neurotrophic keratopathy. METHODS: This is a prospective, noncomparative interventional study. The study included 27 eyes of 24 patients with neurotrophic keratopathy who were unresponsive to conventional therapy. Patients were treated with 10 mg of oral nicergoline twice daily for at least 2 weeks. Slit-lamp examination, photography, corneal fluorescein dye testing, Cochet-Bonnet corneal sensitivity, and best-corrected visual acuity tests were performed before and after treatment. Tear nerve growth factor levels were measured before and after treatment. RESULTS: In 23 eyes (85%), epithelial defects healed completely between 7 and 30 days of treatment with nicergoline (mean, 15.6 ± 8.0 days). Epithelial defects persisted in 4 eyes (15%). The mean corneal sensitivity before and after treatment with nicergoline was 20.5 ± 8.5 and 30.2 ± 10.8 mm, respectively (P < 0.001). The best-corrected visual acuity (measured in units according to the logarithm of the minimum angle of resolution) was significantly improved from 1.1 ± 0.6 to 0.8 ± 0.6 (P < 0.001). The tear nerve growth factor levels were significantly higher ranging from 3.2 ± 0.3 to 6.2 ± 0.3 pg/mL (P < 0.001). CONCLUSIONS: Treatment with nicergoline helps patients with neurotrophic keratopathy in whom conventional treatment has failed.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos alfa/uso terapêutico
Úlcera da Córnea/tratamento farmacológico
Nicergolina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Úlcera da Córnea/metabolismo
Úlcera da Córnea/fisiopatologia
Esquema de Medicação
Feminino
Seres Humanos
Masculino
Meia-Idade
Fator de Crescimento Neural/metabolismo
Estudos Prospectivos
Lágrimas/metabolismo
Acuidade Visual/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 9061-61-4 (Nerve Growth Factor); JCV8365FWN (Nicergoline)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150128
[St] Status:MEDLINE
[do] DOI:10.1097/ICO.0000000000000348


  7 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25591522
[Au] Autor:Kovalchuk VV
[Ti] Título:[Treatment of cognitive and psychoemotional disorders in poststroke patients].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;114(10):81-6, 2014.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy of the drug sermion (nicergoline) in poststroke patients with cognitive and psychoemotional disorders. MATERIAL AND METHODS: The study included 880 patients, including 440 patients with depression and 440 with cognitive impairment, mean age of patients was 69,6 years. The restoration of cognitive functions was followed up using MMSE scales, psychoemotional condition was assessed with the Beck Depression Questionnaire and the Wakefield Depression Scale. RESULTS AND CONCLUSION: The efficacy of sermion has been demonstrated. Application of this drug in the rehabilitation of stroke patients significantly contributes to the improvement of cognitive functions and normalization of mental and emotional state of patients.
[Mh] Termos MeSH primário: Cognição
Emoções
Nicergolina/uso terapêutico
Nootrópicos/uso terapêutico
Reabilitação do Acidente Vascular Cerebral
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Acidente Vascular Cerebral/tratamento farmacológico
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nootropic Agents); JCV8365FWN (Nicergoline)
[Em] Mês de entrada:1503
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150117
[St] Status:MEDLINE


  8 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25409414
[Au] Autor:Salentinig S; Tangso KJ; Hawley A; Boyd BJ
[Ad] Endereço:Drug Delivery, Disposition and Dynamics, and §ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus) , 381 Royal Parade, Parkville, VIC 3052, Australia.
[Ti] Título:pH-driven colloidal transformations based on the vasoactive drug nicergoline.
[So] Source:Langmuir;30(49):14776-81, 2014 Dec 16.
[Is] ISSN:1520-5827
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The structure of colloidal self-assembled drug delivery systems can be influenced by intermolecular interactions between drug and amphiphilic molecules, and is important to understand in the context of designing improved delivery systems. Controlling these structures can enable controlled or targeted release systems for poorly water-soluble drugs. Here we present the interaction of the hydrophobic vasoactive drug nicergoline with the internal structure of nanostructured emulsion particles based on the monoglyceride-water system. Addition of this drug leads to modification of the internal bicontinuous cubic structure to generate highly pH-responsive systems. The colloidal structures were characterized with small-angle X-ray scattering and visualized using cryogenic transmission electron microscopy. Reversible transformations to inverse micelles at high pH, vesicles at low pH, and the modification of the spacing of the bicontinuous cubic structure at intermediate pH were observed, and enabled the in situ determination of an apparent pKa for the drug in this system--a difficult task using solution-based approaches. The characterization of this phase behavior is also highly interesting for the design of pH-responsive controlled release systems for poorly water-soluble drug molecules.
[Mh] Termos MeSH primário: Coloides/química
Sistemas de Liberação de Medicamentos
Nicergolina/química
[Mh] Termos MeSH secundário: Concentração de Íons de Hidrogênio
Microscopia Eletrônica de Transmissão
Estrutura Molecular
Solubilidade
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Colloids); 059QF0KO0R (Water); JCV8365FWN (Nicergoline)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:141216
[Lr] Data última revisão:
141216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141120
[St] Status:MEDLINE
[do] DOI:10.1021/la503824z


  9 / 341 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25389540
[Au] Autor:Damulin IV
[Ti] Título:[Dementia and small vessel diseases of the brain].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;114(8):105-10, 2014.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Clinical and pathogenetic characteristics of dementia caused by small vessel lesions are presented. It is emphasized that this variant of vascular dementia is the most frequent in clinical practice. Clinical examination, accurate assessment of the disease history and using of modern neuroimaging techniques are important for the diagnosis. The drugs that impact on risk factors, including disaggregants, and metabolic drugs (nicergoline) are widely used in the treatment of dementia. These drugs are highly effective and safe.
[Mh] Termos MeSH primário: Doenças de Pequenos Vasos Cerebrais/complicações
Doenças de Pequenos Vasos Cerebrais/tratamento farmacológico
Demência Vascular/diagnóstico
Demência Vascular/tratamento farmacológico
Nicergolina/uso terapêutico
[Mh] Termos MeSH secundário: Doença de Alzheimer/diagnóstico
Doença de Alzheimer/tratamento farmacológico
Doença de Alzheimer/etiologia
Encéfalo/irrigação sanguínea
Demência Vascular/etiologia
Seres Humanos
Neuroimagem
Fatores de Risco
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
JCV8365FWN (Nicergoline)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141113
[St] Status:MEDLINE


  10 / 341 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25243157
[Au] Autor:Saletu B; Garg A; Shoeb A
[Ad] Endereço:Section of Sleep Research and Pharmacopsychiatry, Department of Psychiatry, Medical University of Vienna, Waehringer Guertel, 1090 Vienna, Austria.
[Ti] Título:Safety of nicergoline as an agent for management of cognitive function disorders.
[So] Source:Biomed Res Int;2014:610103, 2014.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Nicergoline is a semisynthetic ergot derivative and has a selective alpha-1A adrenergic receptor blocking property and also other additional mechanisms of actions, both in the brain and in the periphery. It is in clinical use for over three decades in over fifty countries for conditions such as cerebral infarction, acute and chronic peripheral circulation disorders, vascular dementia, and Alzheimer's disease and has been found to be beneficial in a variety of other conditions. However, concerns about its safety have been raised, especially after the European medicines agency's (EMEA's) restriction in the use of all ergot derivatives including nicergoline. But, most of the available literature and data suggest that the adverse events with nicergoline are mild and transient. Further, none of the available treatment options for cognitive disorders afford definitive resolution of symptoms. In this backdrop, we discuss the pharmacology of nicergoline with special emphasis on the safety of this compound, especially when used in patients suffering from cognitive function disorders.
[Mh] Termos MeSH primário: Transtornos Cognitivos/tratamento farmacológico
Nicergolina/efeitos adversos
Nootrópicos/efeitos adversos
[Mh] Termos MeSH secundário: Interações Medicamentosas
Ergotismo
Fibrose
Seres Humanos
Nicergolina/farmacocinética
Nicergolina/farmacologia
Nicergolina/uso terapêutico
Nootrópicos/farmacocinética
Nootrópicos/farmacologia
Nootrópicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Nootropic Agents); JCV8365FWN (Nicergoline)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:170503
[Lr] Data última revisão:
170503
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140923
[St] Status:MEDLINE
[do] DOI:10.1155/2014/610103



página 1 de 35 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde